

January 2025

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. Hikma has an established and growing presence in Europe, having operated there since the 1990s. Through our high-quality manufacturing plants in Portugal, Italy and Germany, we supply generic injectable medicines to North America, Europe, and Middle East and North Africa (MENA).

## Local expertise, global strength

 **3** locations with **5** manufacturing plants

 **1,300+** skilled employees

 **2** R&D centres

 **7** commercial offices

## Manufacturing capabilities

With an installed capacity of over 500 million units, expansion is underway in both the EU and the US.

### Sintra, Portugal, the global hub for the Injectables business:

- Three segregated plants for the manufacturing of general formulation products, high containment products and Cephalosporins antibiotics
- Our capabilities cover different forms and technologies, including vials and ampoules, prefilled syringes, IV bags, emulsions/suspensions and oils
- The site services, the US, EU, UK and MENA markets

### Goslar, Germany:

- One plant
- Our capabilities include cytotoxic manufacturing of both liquid and lyophilised vials
- The site services the US, EU and MENA markets

### Pavia, Italy:

- One plant
- Our capabilities include liquid and lyophilised vials, and liquid ampoules
- The site services the EU and MENA markets

## R&D sites

 Sintra, Portugal

 Zagreb, Croatia

## Integrated CMO services

Our contract manufacturing integrated services for injectable products offer a range of capabilities, ensuring high-quality at every stage and supporting our partners needs from industrial process development all the way to commercial manufacturing.

## Commercial offices

We supply high-quality medicines to European hospitals and retail markets.

- | Austria
- | BENELUX
- | France
- | Germany
- | Italy
- | Portugal
- | Spain
- | UK and Nordics



## Therapy areas

 Anti-infectives

 Central Nervous System

 Cardiovascular

 Oncology

 Musculoskeletal

 Respiratory

 Digestive and metabolic system

 Anti-neoplastics and Hormonal therapy

**Company information**  
Chief Executive Officer:  
Riad Mishlawi

Chief Financial Officer:  
Khalid Nablsi

**Hikma Pharmaceuticals PLC**  
1 New Burlington Place London  
W1S2HR, UK

**Contacts**  
See [www.hikma.com](http://www.hikma.com) for contact forms